Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics

Circulation

Volumn 140, Issue 4, 2019, Pages 316-318

  Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

diabetes mellitus; Editorials; fluorescence; glomerular filtration rate; hemodynamics; microscopy; multiphoton; sodium glucose transporter 2 inhibitors; Type 2

Indexed keywords

ADENOSINE; CANAGLIFLOZIN; CREATININE; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

CAPILLARY PERMEABILITY; CREATININE BLOOD LEVEL; EDITORIAL; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GLOMERULUS CAPILLARY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; ULTRAFILTRATION; URINARY EXCRETION; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; HEMODYNAMICS; MOUSE;

ANIMALS; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSIDES; HEMODYNAMICS; MICE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85073676711     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.040326     Document Type: Editorial

References (8)

1. Kidokoro K, Cherney DZ, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019; 140: 303-315. doi: 10.1161/CIRCULATIONAHA.118.037418
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869. doi: 10.1056/NEJMoa011161
3. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-334. doi: 10.1056/NEJMoa1515920
4. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018; 6: 691-704. doi: 10.1016/S2213-8587(18)30141-4
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-357. doi: 10.1056/NEJMoa1812389
6. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-597. doi: 10.1161/CIRCULATIONAHA.113.005081
7. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPAREG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018; 137: 119-129. doi: 10.1161/CIRCULATIONAHA.117.028268
8. Zhang J, Wei J, Jiang S, Xu L, Wang L, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. Macula densa SGLT1-NOS1-Tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol. 2019; 30: 578-593. doi: 10.1681/ASN.2018080844